DOCSLIB.ORG

Laboratory Seizures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laboratory Seizures MANUFACTURE SEIZURES OF ILLICIT LABORATORIES REPORTED FOR 2007 - 2008* *Remark: For convenience, an attempt was made to group the reported estimates by drug categories. However, due to inconsistencies no overall analysis of the data is shown. Where available, 2008 data is reported. Numbers are presented as reported and should be interpreted with caution. Figures refer to all laboratories, regardless of the size of the establishment or the scale of the output. Region/country or territory Year Name of drug seized Number of laboratories Source OPIATE GROUP Americas North America Mexico 2007 Heroin 4 Lab. 2008 Heroin 1 Lab. Subtotal North America 5 Lab. South America Colombia 2007 Heroin 2 Lab. 2008 Heroin 4 Lab. Peru 2008 Opium 1 Lab. Subtotal South America 7 Lab. Total Americas 12 Lab. Asia East and South-East Asia China 2007 Ketamine 44 Lab. 2007 Heroin 8 Lab. 2007 Opium 1 Lab. Myanmar 2008 Heroin 5 Lab. Subtotal East and South-East Asia 58 Lab. South Asia India 2007 Heroin 1 Lab. Subtotal South Asia 1 Lab. Total Asia 59 Lab. Europe East Europe Belarus 2008 Fentanyl 1 Lab. Russian Federation 2007 Acetylated opium 347 Lab. 2007 Heroin 187 Lab. Govt 2007 Morphine 13 Lab. Govt 2008 Heroin 1 Lab. Subtotal East Europe 549 Lab. West & Central Europe Germany 2007 Fentanyl 1 Lab. Greece 2008 Heroin 2 Lab. Subtotal West & Central Europe 3 Lab. Total Europe 552 Lab. Oceania Oceania Australia 2007 Heroin 9 Lab. Govt New Zealand 2007 Heroin 1 Lab. Govt 2008 Heroin 1 Lab. Govt Subtotal Oceania 11 Lab. Region/country or territory Year Name of drug seized Number of laboratories Source Total Oceania 11 Lab. Opiate group 634 Lab. Sources: Annual Reports Questionnaire if not otherwise stated. UNODC Field Office (FO), International Narcotics Control Strategy Report ( INCSR), Government (Govt.). MANUFACTURE SEIZURES OF ILLICIT LABORATORIES REPORTED FOR 2007 - 2008* *Remark: For convenience, an attempt was made to group the reported estimates by drug categories. However, due to inconsistencies no overall analysis of the data is shown. Where available, 2008 data is reported. Numbers are presented as reported and should be interpreted with caution. Figures refer to all laboratories, regardless of the size of the establishment or the scale of the output. Region/country or territory Year Name of drug seized Number of laboratories Source COCA GROUP Africa Southern Africa South Africa 2007 crack 1 Lab. Subtotal Southern Africa 1 Lab. Total Africa 1 Lab. Americas North America Mexico 2007 Cocaine 1 Lab. Subtotal North America 1 Lab. South America Argentina 2008 Cocaine HCL 20 Lab. Bolivia (Plurinational State of) 2007 Cocaine HCL 7 Lab. Govt 2007 Cocaine base 4076 Lab. Govt 2008 Cocaine HCL 7 Lab. Govt 2008 Cocaine base 4988 Lab. Govt Chile 2007 Cocaine 5 Lab. 2008 Cocaine HCL 4 Lab. Colombia 2007 HCL 285 Lab. 2007 Coca paste 318 Lab. 2007 Coca base 1868 Lab. 2008 Coca base 2736 Lab. 2008 Coca paste 411 Lab. 2008 HCL 296 Lab. Ecuador 2007 Cocaine 1 Lab. Peru 2007 Cocaine 16 Lab. 2007 PBC 649 Lab. 2008 Cocaine base 1205 Lab. 2008 Cocaine HCL 19 Lab. Venezuela (Bolivarian Republic of) 2008 Cocaine 10 Lab. Subtotal South America 16921 Lab. Total Americas 16922 Lab. Europe East Europe Moldova (Republic of) 2008 Cocaine HCL 1 Lab. Subtotal East Europe 1 Lab. West & Central Europe Greece 2008 Cocaine base 1 Lab. Netherlands 2008 Cocaine 4 Lab. Govt Portugal 2007 Cocaine HCL Govt Spain 2007 Other 18 Lab. 2008 Cocaine 25 Lab. Subtotal West & Central Europe 48 Lab. Region/country or territory Year Name of drug seized Number of laboratories Source Total Europe 49 Lab. Coca group 16972 Lab. Sources: Annual Reports Questionnaire if not otherwise stated. UNODC Field Office (FO), International Narcotics Control Strategy Report ( INCSR), Government (Govt.). MANUFACTURE SEIZURES OF ILLICIT LABORATORIES REPORTED FOR 2007 - 2008* *Remark: For convenience, an attempt was made to group the reported estimates by drug categories. However, due to inconsistencies no overall analysis of the data is shown. Where available, 2008 data is reported. Numbers are presented as reported and should be interpreted with caution. Figures refer to all laboratories, regardless of the size of the establishment or the scale of the output. Region/country or territory Year Name of drug seized Number of laboratories Source CANNABIS GROUP Africa Southern Africa South Africa 2007 Other 1 Lab. Subtotal Southern Africa 1 Lab. Total Africa 1 Lab. Americas North America Mexico 2007 Marihuana 4 Lab. Subtotal North America 4 Lab. Total Americas 4 Lab. Europe East Europe Belarus 2008 Marijuana 2 Lab. Russian Federation 2007 Resin 559 Lab. Govt 2007 Herb 674 Lab. Govt 2008 Herb 10 Lab. 2008 Resin 10 Lab. Subtotal East Europe 1255 Lab. West & Central Europe Czech Republic 2007 Cannabis 34 Lab. 2008 Cannabis 79 Lab. Lithuania 2007 Cannabis 6 Lab. 2008 Cannabis 2 Lab. Slovakia 2007 Cannabis 5 Lab. 2008 Cannabis 50 Lab. Subtotal West & Central Europe 176 Lab. Total Europe 1431 Lab. Cannabis group 1436 Lab. Sources: Annual Reports Questionnaire if not otherwise stated. UNODC Field Office (FO), International Narcotics Control Strategy Report ( INCSR), Government (Govt.). MANUFACTURE SEIZURES OF ILLICIT LABORATORIES REPORTED FOR 2007 - 2008* *Remark: For convenience, an attempt was made to group the reported estimates by drug categories. However, due to inconsistencies no overall analysis of the data is shown. Where available, 2008 data is reported. Numbers are presented as reported and should be interpreted with caution. Figures refer to all laboratories, regardless of the size of the establishment or the scale of the output. Region/country or territory Year Name of drug seized Number of laboratories Source COMBINED AMPHETAMINE, METHAMPHETAMINE GROUP Americas North America Canada 2008 Amphetamine, methamphetamine (also 2 Lab. producing Ketamine) Subtotal North America 2 Lab. Total Americas 2 Lab. Asia East and South-East Asia Indonesia 2007 Methamphetamine 7 Lab. DNP Subtotal East and South-East Asia 7 Lab. Total Asia 7 Lab. Oceania Oceania Australia 2007 Methamphetamine 328 Lab. Govt Subtotal Oceania 328 Lab. Total Oceania 328 Lab. Combined amphetamine, methamphetamine group 337 Lab. AMPHETAMINE GROUP Americas North America Canada 2008 Amphetamine 3 Lab. United States of America 2007 Amphetamine 3 Lab. Subtotal North America 6 Lab. Total Americas 6 Lab. Asia East and South-East Asia Indonesia 2007 Other 3 Lab. Subtotal East and South-East Asia 3 Lab. Near and Middle East /South-West Asia Lebanon 2007 Captagon 1 Lab. SMA Subtotal Near and Middle East /South-West Asia 1 Lab. Total Asia 4 Lab. Europe East Europe Russian Federation 2007 Amphetamine 62 Lab. Govt 2008 Amphetamine 7 Lab. Subtotal East Europe 69 Lab. Southeast Europe Bulgaria 2007 Amphetamine 1 Lab. Serbia 2007 Amphetamine 1 Lab. 2008 Amphetamine 1 Lab. Region/country or territory Year Name of drug seized Number of laboratories Source Subtotal Southeast Europe 3 Lab. West & Central Europe Belgium 2007 Amphetamine 7 Lab. 2008 Amphetamine 4 Lab. Estonia 2007 Amphetamine 1 Lab. Germany 2007 Amphetamine 5 Lab. 2008 Amphetamine 8 Lab. Iceland 2008 Amphetamine 1 Lab. SMA Lithuania 2008 Amphetamine 1 Lab. Netherlands 2007 Amphetamine 5 Lab. 2008 Amphetamine 3 Lab. Govt 2008 Unknown 11 Lab. Govt Poland 2007 Amphetamine 13 Lab. 2008 Amphetamine 16 Lab. Subtotal West & Central Europe 75 Lab. Total Europe 147 Lab. Amphetamine group 157 Lab. COMBINED AMPHETAMINE, METHAMPHETAMINE AND ECSTASY GROUP Americas North America Canada 2008 Methamphetamine and Ecstasy 2 Lab. Subtotal North America 2 Lab. Total Americas 2 Lab. Asia East and South-East Asia Malaysia 2007 Methamphetamine and Ecstasy 9 Lab. F.O Subtotal East and South-East Asia 9 Lab. Total Asia 9 Lab. Combined amphetamine, methamphetamine and ecstasy group 11 Lab. METHAMPHETAMINE GROUP Africa Southern Africa South Africa 2007 Methamphetamine 12 Lab. 2008 Methamphetamine 20 Lab. SMA Subtotal Southern Africa 32 Lab. Total Africa 32 Lab. Americas North America Canada 2007 Methamphetamine 17 Lab. 2008 Methamphetamine 7 Lab. Mexico 2007 Methamphetamine 22 Lab. 2008 Methamphetamine 21 Lab. United States of America 2007 Methamphetamine 5693 Lab. 2007 Ice 17 Lab. 2008 Methamphetamine 7225 Lab. Subtotal North America 13002 Lab. South America Argentina 2008 Methamphetamine 1 Lab. Subtotal South America 1 Lab. Total Americas 13003 Lab. Asia Central Asia and Transcaucasian countries Kazakhstan 2008 Methamphetamine 1 Lab. Govt Region/country or territory Year Name of drug seized Number of laboratories Source Subtotal Central Asia and Transcaucasian countries 1 Lab. East and South-East Asia Cambodia 2007 Methamphetamine 2 Lab. F.O China 2007 Methamphetamine & other ATS 75 Lab. Indonesia 2008 Shabu 5 Lab. Korea (Republic of) 2007 Methamphetamine 1 Lab. Myanmar 2007 Methamphetamine 5 Lab. 2008 Methamphetamine 1 Lab. Philippines 2007 Methamphetamine 9 Lab. F.O 2008 Methamphetamine 10 Lab. Thailand 2008 Methamphetamine 1 Lab. SMA Subtotal East and South-East Asia 109 Lab. Near and Middle East /South-West Asia Iran (Islamic Republic of) 2008 Methamphetamine 4 Lab. Subtotal Near and Middle East /South-West Asia 4 Lab. South Asia India 2008 Methamphetamine 1 Lab. Sri Lanka 2008 Methamphetamine 1 Lab. Subtotal South Asia 2 Lab. Total Asia 116 Lab. Europe East Europe Belarus 2008 Methamphetamine 3 Lab. Subtotal East Europe 3 Lab. West & Central Europe Austria 2007 Methamphetamine 1 Lab. Govt 2008 Methamphetamine 3 Lab. Czech Republic 2007 Methamphetamine 388 Lab. 2008 Methamphetamine 434 Lab. Germany 2007 Methamphetamine 3 Lab. 2008 Methamphetamine 12 Lab. Netherlands 2008 Methamphetamine 2 Lab. Govt Poland 2007 Methamphetamine 1 Lab. Portugal 2007 Methamphetamine 1 Lab. Govt 2008 Methamphetamine 1 Lab. Govt Slovakia 2007 Methamphetamine 12 Lab. 2008 Methamphetamine 150 Lab. Subtotal West & Central Europe 1008 Lab. Total Europe 1011 Lab. Oceania Oceania Australia 2008 Methamphetamine 260 Lab. New Zealand 2007 Methamphetamine 190 Lab. 2008 Methamphetamine 133 Lab. Subtotal Oceania 583 Lab. Total Oceania 583 Lab. Methamphetamine group 14745 Lab.
Load more

Recommended publications
  • Interactions Between Ethanol and Cocaine, Amphetamine, Or MDMA in the Rat: Thermoregulatory and Locomotor Effects
    Psychopharmacology DOI 10.1007/s00213-007-1007-5 ORIGINAL INVESTIGATION Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects Sami Ben Hamida & Erin Plute & Brigitte Cosquer & Christian Kelche & Byron C. Jones & Jean-Christophe Cassel Received: 22 May 2007 /Accepted: 29 October 2007 # Springer-Verlag 2007 Abstract duced by EtOH alone. Conversely, EtOH attenuated Rationale (±)-3,4-methylenedioxymethamphetamine MDMA-related hyperthermia, an effect increasing across (MDMA, ecstasy) is often taken recreationally with ethanol treatment days. These results demonstrate that the interac- (EtOH). In rats, EtOH may potentiate MDMA-induced tion between MDMA and EtOH may be different from the hyperactivity, but attenuate hyperthermia. interaction between EtOH and AMPH or COCA. Objective Experiment 1 compared the interactions between Conclusion Because of potential health-related consequen- EtOH (1.5 g/kg) and MDMA (6.6 mg/kg) with EtOH + ces of such polydrug misuse, it is worth identifying the cocaine (COCA; 10 mg/kg) and EtOH + amphetamine mechanisms underlying these interactions, especially be- (AMPH; 1 mg/kg) on locomotor activity and thermoregu- tween EtOH and MDMA. Given the different affinity lation. Experiment 2 used a weaker dose of MDMA profiles of the three drugs for serotonin, dopamine, and (3.3 mg/kg) and larger doses of COCA (20 mg/kg) and norepinephrine transporters, our results appear compatible AMPH (2 mg/kg). with the possibility of an important role of serotonin in at Materials and methods Drug treatments were administered least the EtOH-induced potentiation of MDMA-induced on four occasions (2, 5, and 2 days apart, respectively; hyperlocomotion.
    [Show full text]
  • A User's Guide to Methamphetamine
    A USER’S GUIDE TO METHAMPHETAMINE A self-help guide to reduce harm for people who use methamphetamine 1st Edition, March 2017 Acknowledgements This booklet was adapted from an original publication created by The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. This information does not constitute medical advice. Please seek the immediate help of a qualified medical practitioner about any personal health concerns. This booklet is being distributed for information purposes only. In the current state of crisis related to crystal methamphetamine, this booklet is intended as a guide to reduce harm for people who use methamphetamine. It lists the most common features of methamphetamine use, ways to reduce harm associated with the use of meth, and strategies for cutting down and quitting. The best way to avoid problems with drugs is to not use them. We are grateful for the contributions of the Integrated Drug Strategies in Waterloo Region and Guelph Wellington, in particular the leadership of Adrienne Crowder and Lindsay Sprague. Don Roth, Kerry Manthenga, Shirley Hilton, and our community review team provided great support and helpful edits. Marcey Gray provided exemplary skill on the design, images and editing, with final expert assistance from Arkay Design and Print. We are thankful for the financial support to print copies from the Waterloo-Wellington Human Services and Justice Coordinating Committee. For more information please contact: Wellington Guelph Drug Strategy www.wgdrugstrategy.ca Waterloo Region Integrated Drugs Strategy www.waterlooregiondrugstrategy.ca Circulated with the support of: WaterlooRegion Integrated Drugs Strategy WaterlooRegion Integrated Drugs Strategy The best way to avoid problems with drugs is to not use them.
    [Show full text]
  • Booklet 4 Stimulants Preface
    4 STIMULANTS 4 STIMULANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking.
    [Show full text]
  • Do You Know... Cocaine
    Do You Know... Street names: blow, C, coke, crack, flake, freebase, rock, snow Cocaine What is cocaine? Cocaine is a stimulant drug. Stimulants make people feel more alert and energetic. Cocaine can also make people feel euphoric, or “high.” Pure cocaine was first isolated from the leaves of the coca bush in 1860. Researchers soon discovered that cocaine numbs whatever tissues it touches, leading to its use as a local anesthetic. Today, we mostly use synthetic anesthetics, rather than cocaine. In the 1880s, psychiatrist Sigmund Freud wrote scientific papers that praised cocaine as a treatment for many ailments, including depression and alcohol and opioid addiction. After this, cocaine became widely and legally available in patent medicines and soft drinks. As cocaine use increased, people began to discover its dangers. In 1911, Canada passed laws restricting the importation, manufacture, sale and possession of cocaine. The use of 1/4 © 2003, 2010 CAMH | www.camh.ca cocaine declined until the 1970s, when it became known How does cocaine make you feel? for its high cost, and for the rich and glamorous people How cocaine makes you feel depends on: who used it. Cheaper “crack” cocaine became available · how much you use in the 1980s. · how often and how long you use it · how you use it (by injection, orally, etc.) Where does cocaine come from? · your mood, expectation and environment Cocaine is extracted from the leaves of the Erythroxylum · your age (coca) bush, which grows on the slopes of the Andes · whether you have certain medical or psychiatric Mountains in South America.
    [Show full text]
  • Section 124.401 (31, 2) §124.401, CONTROLLED SUBSTANCES 2
    1 CONTROLLED SUBSTANCES, §124.401 124.401 Prohibited acts — manufacture, delivery, possession — counterfeit substances, simulated controlled substances, imitation controlled substances — penalties. 1. Except as authorized by this chapter, it is unlawful for any person to manufacture, deliver, or possess with the intent to manufacture or deliver, a controlled substance, a counterfeit substance, a simulated controlled substance, or an imitation controlled substance, or to act with, enter into a common scheme or design with, or conspire with one or more other persons to manufacture, deliver, or possess with the intent to manufacture or deliver a controlled substance, a counterfeit substance, a simulated controlled substance, or an imitation controlled substance. a. Violation of this subsection, with respect to the following controlled substances, counterfeit substances, simulated controlled substances, or imitation controlled substances, is a class “B” felony, and notwithstanding section 902.9, subsection 1, paragraph “b”, shall be punished by confinement for no more than fifty years and a fine of not more than one million dollars: (1) More than one kilogram of a mixture or substance containing a detectable amount of heroin. (2) More than five hundred grams of a mixture or substance containing a detectable amount of any of the following: (a) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine and their salts have been removed. (b) Cocaine, its salts, optical and geometric isomers, or salts of isomers. (c) Ecgonine, its derivatives, their salts, isomers, or salts of isomers. (d) Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subparagraph divisions (a) through (c).
    [Show full text]
  • 1.2 Coca / Cocaine Market
    1.2 Coca / cocaine market 1.2.1 Summary trend overview 1.2.2 Production Cultivation In 2008, a significant decrease in Colombia, the world’s In 2008, the total area under coca cultivation decreased largest cultivator of coca bush, brought the total area by 8% due to a significant reduction in Colombia under coca cultivation down by some 8% to 167,600 (-18%), which was not offset by small increases in the ha. Total cultivation is close to the average level since Plurinational State of Bolivia (6%) and Peru (4%). The 2002, and well below the levels reached in the 1990s. total area under coca cultivation decreased to 167,600 Similarly, the estimated global cocaine production also ha, which is well below the level reached in the 1990s. decreased in 2008, due to a strong reduction in Colom- In spite of this decrease, Colombia remained the world’s bia. The Plurinational State of Bolivia and Peru both largest coca bush-cultivating country with 81,000 ha, registered small increases in cultivation and produc- followed by Peru (56,100 ha) and Bolivia (30,500 ha). tion. Most of the decrease of 18,000 ha in Colombia hap- Compared to the record high in 2005, cocaine seizures pened in the regions of Meta-Guaviare and Putumayo- decreased in 2007. The Americas account for the vast Caquetá. However, a significant increase was observed in majority of the world’s cocaine seizures, although a sig- the Pacific region as well as in some smaller cultivation nificant decline in trafficking towards North America, regions.
    [Show full text]
  • Prescription Drugs More Teens Abuse Prescription Drugs Than Any Illicit Drug Except Marijuana
    ® DRUG FACT SHEET Alcohol Consuming energy drinks mixed with alcohol results in an increase in the number of alcohol-related injuries because the perception of impairment is diminished. Class of drug: Depressant Main active ingredient: Ethanol/Ethyl alcohol, which is made by fermenting or distilling grains, fruit and vegetables, is the main ingredient. Alcohol is found in beverages like beer, wine, coolers and hard liquor like rum and vodka. What it looks like: Liquid, either clear or colored A standard drink is equal to .6 oz of pure alcohol, which is equal to 12 oz of beer, Street names: Booze, Juice, Spirits, Brew, Sauce 8 oz of malt liquor, 5 oz of wine and 1.5 oz or a “shot” of 80-proof liquor (e.g. gin, How it is used: Taken orally rum, vodka). Duration of high: Effects of high can last from one to four hours. The effect of alcohol on the body by volume is the same. It is the amount of ethanol consumed that affects a person most, not the type of alcoholic drink. Withdrawal symptoms: Restlessness, sweating, tremors, insomnia, anxiety, c onvulsions, death Detected in the body: With a healthy liver, an average person can Indiana information eliminate one drink (.6 oz of alcohol) per hour. Detection time in urine is one to two days. In 2011, 17.6 percent of high school students in Indiana re - Effects: Physical —small amounts can produce relaxed ported that they drank alcohol muscles, headache, nausea; somewhat large for the first time before the age amounts can cause slurred speech, double vision; very large amounts can cause respiratory of 13.
    [Show full text]
  • BETWEEN COCA and COCAINE: a Century Or More of U.S.-Peruvian Drug Paradoxes, 1860-1980
    Number 251 BETWEEN COCA AND COCAINE: A Century or More of U.S.-Peruvian Drug Paradoxes, 1860-1980 Paul Gootenberg, with Commentary by Julio Cotler Professor Paul Gootenberg The Woodrow Wilson Center, Washington Latin American Program Department of History, SUNY-Stony Brook Copyright February 2001 This publication is one of a series of Working Papers of the Latin American Program of the Woodrow Wilson International Center for Scholars. The series includes papers in the humanities and social sciences from Program fellows, guest scholars, workshops, colloquia, and conferences. The series aims to extend the Program's discussions to a wider community throughout the Americas, to help authors obtain timely criticism of work in progress, and to provide, directly or indirectly, scholarly and intellectual context for contemporary policy concerns. Single copies of Working Papers may be obtained without charge by writing to: Latin American Program Working Papers The Woodrow Wilson International Center One Woodrow Wilson Plaza 1300 Pennsylvania Avenue, NW Washington, D.C. 20004-3027 The Woodrow Wilson International Center for Scholars was created by Congress in 1968 as a "living institution expressing the ideals and concerns of Woodrow Wilson, symbolizing and strengthening the fruitful relations between the world of learning and the world of public affairs." The Center's Latin American Program was established in 1977. LATIN AMERICAN PROGRAM STAFF Joseph S. Tulchin, Director Cynthia Arnson, Assistant Director Luis Bitencourt, Director, Brazil @ the
    [Show full text]
  • Methamphetamine Use: Lessons Learned
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Methamphetamine Use: Lessons Learned Author(s): Dana Hunt, Ph.D.; Sarah Kuck; Linda Truitt, Ph.D. Document No.: 209730 Date Received: February 2006 Award Number: 99-C-008 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. ANALYTIC SUPPORT PROGRAM CONTRACT TASK REQUIREMENT T-043: Methamphetamine Use: Lessons Learned Contract No. 99-C-008 Cambridge, MA Lexington, MA Hadley, MA Bethesda, MD Chicago, IL January 31, 2006 Prepared for Raymond C. German Contracting Officer Christine Crossland Senior Social Science Analyst National Institute of Justice Office of Justice Programs Acquisition Management Division 810 Seventh Street, SW Washington, D.C. 20001 Prepared by Dana Hunt, Ph.D. Sarah Kuck Abt Associates Inc. Linda Truitt, Ph.D. 55 Wheeler Street Cambridge, MA 02138 Contents Executive Summary...............................................................................................................iii History of Methamphetamine Use .................................................................................iii Trends.............................................................................................................................iii
    [Show full text]
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture Of
    ANNEXES Annex IV Use of scheduled substances in the illicit manufacture of narcotic drugs and psychotropic substances Figures I–V below depict the use of scheduled substances in the illicit manufacture of narcotic drugs and psychotropic substances. The approximate quantities provided are based on common manufacturing methods. Other manufacturing methods using scheduled substances — or even non-scheduled substances instead of or in addition to scheduled substances — may also be encountered, depending on the geographical location. Figure I. Illicit manufacture of cocaine and heroin: scheduled substances and the approximate quantities thereof required for the illicit manufacture of 100 kilograms of cocaine or heroin hydrochloride Coca leaf Opium Sulphuric acid (100–300 litres) Coca base/paste Morphine Potassium permanganate Acetic anhydride (20–55 kilograms) (100–250 litres) Cocaine Heroin Acetone/ethyl ether/ Acetone/ethyl ether methyl ethyl ketone/toluene (10–100 litres) (1,000–2,000 litres) Hydrochloric acid Hydrochloric acid (30–40 litres) (20–40 litres) Cocaine hydrochloride Heroin hydrochloride (100 kilograms) (100 kilograms) Note: The extraction of cocaine from coca leaf and the purification of coca paste and the crude base products of cocaine and heroin require solvents, acids and bases. A wide range of such chemicals are used at all stages of drug manufacture. 55 PRECURSORS Figure II. Illicit manufacture of amphetamine and methamphetamine: scheduled substances and the approximate quantities thereof required for the illicit manufacture
    [Show full text]
  • PDF (Crack and Cocaine)
    Crack and Cocaine Brief Intervention Programmes © COCA/Rugby House 2006 1 Contents: 1. Introduction 3 2. Brief Intervention Sessions - Introduction 5 3. Training and Supervision 14 Low Threshold 2-week Programme 16 4. Low Threshold sessions 17 12-week Brief Intervention Programme 19 5. Session 1 Introduction & 12 week goals 20 6. Session 2 How crack and cocaine work 23 7. Session 3 Health implications 34 8. Session 4 Closing the door on scoring 41 9. Session 5 Cycles of use 44 10. Session 6 Patterns of use 47 11. Session 7 Triggers 50 12. Session 8 Cravings 53 13. Session 9 Euphoric recall 56 14. Session 10 Connections with crime 59 15. Session 11 Potentially dangerous situations 62 16. Session 12 After Care and Support 65 Bibliography 68 Appendices 72 – 136 © COCA/Rugby House 2006 2 1. Introduction: These Intervention Programmes for crack and cocaine users were commissioned by the National Treatment Agency for Substance Misuse both as part of its Resource Database of Psychosocial Interventions (PSI) and as a standalone publication. The PSI Resource Database is an element of the Treatment Effectiveness Strategy designed to assist practitioners in improving the quality of treatment provision available to substance misusing clients. It aims to provide a resource comprising either evidence-based or expert panel-derived protocols for effective treatments for such clients. It is hoped that services will use the framework to identify treatment protocols relevant to their clients’ needs and the training and supervision requirements for their staff to be able to deliver the protocols. The two separate manualised Crack and Cocaine Interventions included here are protocols commissioned by the NTA from experts in the UK who are familiar with the treatment context.
    [Show full text]
  • COCAINE (Street Names: Coke, Snow, Crack, Rock) December 2019 Introduction: Exposures) and 30 Deaths Related to Cocaine in 2017
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section COCAINE (Street Names: Coke, Snow, Crack, Rock) December 2019 Introduction: exposures) and 30 deaths related to cocaine in 2017. And, for 2018, Cocaine abuse has a long, deeply rooted history in U. S. drug there were 5,778 exposures, 1,358 single substance exposures, and culture, both urban and rural. It is an intense and euphorigenic drug 28 deaths. with strong addictive potential. With the advent of the free-base form of cocaine (“crack”), and its easy availability on the street, cocaine User Population: continues to burden both law enforcement and health care systems in Recent findings indicate that cocaine use may be re-emerging as the U.S. a public health concern in the United States. According to the National Survey on Drug Use and Health (NSDUH), survey estimates indicate Licit Uses: that in 2015, 968,000 people aged 12 or older initiated cocaine use in Cocaine hydrochloride (4% and 10%) solution is used primarily the past year (0.4 percent of the population), which was higher than as a topical local anesthetic for the upper respiratory tract. The vaso- in each of the years from 2008 to 2014. The 2015 estimate represents constrictor and local anesthetic properties of cocaine cause a 26 percent increase compared with 2014, with 766,000 new cocaine anesthesia and mucosal shrinkage. It constricts blood vessels and users in the past year (0.3 percent of the population), and a 61 percent reduces blood flow, and is used to reduce bleeding of the mucous increase compared with 2013, with 601,000 new cocaine users in the membranes in the mouth, throat, and nasal cavities.
    [Show full text]